Abstract
We have investigated a new source of commercial Lewis and P1 soluble blood group substances produced for use in immunohematology. Our tests show them to be potent, specific, stable and suitable for use in antibody inhibition procedures. They should make a useful contribution to antibody identification studies in hospital blood bank laboratories.